Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

The Netherlands Cancer Institute

InstitutionResearch output, impact & collaborations

The Netherlands Cancer Institute is a research organisation in Amsterdam, NL. OpenAlex records 29,793 works and 5,742,475 citations for it. 5,422 researchers list it as their most recent affiliation.

29,793
Works
5,742,475
Citations
5,422
Researchers
69.3
Avg h-index

How has The Netherlands Cancer Institute's publication output changed over time?

ScholarIQpublication output · 1993–2020

Output grew0% over the shown period — from 1 works in 1993 to 1 in 2020.

1
2
1
1
3
2
1
1
19931998201220152016201720182020

Who are the most-cited researchers behind The Netherlands Cancer Institute?

ScholarIQtop researchers by citations
1
Wim H. van Harten · Health Systems, Economic Evaluations, Quality of Life
319 works8,862 citations
2
Sonja Levy · Neuroendocrine Tumor Research Advances
21 works239 citations
3
Z Al-Khayat · Health Systems, Economic Evaluations, Quality of Life
4 works2 citations
4
Valesca P Retèl · Health Systems, Economic Evaluations, Quality of Life
1 works0 citations

What are the most-cited papers on The Netherlands Cancer Institute?

ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Science. 20157,996 Citations
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
The Lancet. 20163,735 Citations
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Barbara Gandek, John E. Ware, Neil K. Aaronson, Giovanni Apolone, Jakob Bue Bjørner, John Brazier, Monika Bullinger, Stein Kaasa, Alain Leplège, Luis Prieto, Marianne Sullivan
Journal of Clinical Epidemiology. 19982,916 Citations
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes, Kelly‐Anne Phillips, Thea M. Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E. van Leeuwen, Roger L. Milne, Nadine Andrieu, David E. Goldgar, Mary Beth Terry, Matti A. Rookus, Douglas F. Easton, Antonis C. Antoniou, Lesley McGuffog, D. Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Rosalind A. Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Noguès, Christine Lasset, Dominique Stoppa‐Lyonnet, Jean‐Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J. Hooning, Lizet E. van der Kolk, Carolien M. Kets, Muriel A. Adank, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Melissa C. Southey, Mary B. Daly, Saundra S. Buys, Ana Osório, Christoph Engel, Karin Kast, Rita K. Schmutzler, Trinidad Caldés, Anna Jakubowska, Jacques Simard, Michael Friedländer, Sue‐Anne McLachlan, Eva Macháčková, Lenka Foretová, Yen Y. Tan, Christian F. Singer, Edith Oláh, Anne‐Marie Gerdes, Brita Arver, Håkan Olsson
JAMA. 20172,909 CitationsOPEN ACCESS
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
New England Journal of Medicine. 20182,881 CitationsOPEN ACCESS

Who collaborates most closely around The Netherlands Cancer Institute?

ScholarIQco-authorship network
United States
29%
Germany
29%
Netherlands
14%
France
14%
United Kingdom
14%

How much of the research on The Netherlands Cancer Institute is open access?

ScholarIQopen access share
42%OPEN ACCESS
Gold
0%
Green
8%
Hybrid
0%
Bronze
33%
Closed
58%

Related on ScholarIQ

Breast Cancer Treatment Studies
Top Topic
Cancer Immunotherapy and Biomarkers
Top Topic
Cancer Genomics and Diagnostics
Top Topic
Advanced Radiotherapy Techniques
Top Topic
Immunotherapy and Immune Responses
Top Topic
Lung Cancer Treatments and Mutations
Top Topic
470M+ articles · free account